Johnson & Johnson raised its 2026 sales and earnings guidance after exceeding third-quarter analyst expectations. The company now projects operational sales growth between 6.4% and 6.8%. This trajectory positions the firm to potentially surpass $100 billion in annual revenue for the first time.
The Innovative Medicine division drove this performance through significant growth in its oncology drug portfolio. However, the MedTech division reported disappointing sales results during the same period.
Company shares fell nearly 6% following the initial earnings announcement on October 13. Subsequent analysis on October 17 suggests investors view this price decline as a buying opportunity. Analysts maintain a strong buy rating, citing the company's long-term growth potential and robust product pipeline.